Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Adoption, Insights and Patient Engagement with Pete Piliero, VP Med Affairs at Melinta Therapeutics

Sep 15, 202229 minAudio
ShareXLinkedInFacebookWhatsAppEmail

I had a great chat with Pete Piliero, VP of Medical Affairs at Melinta Therapeutics. We talk about: Transitioning from clinical practice to med affairsChanges in how other groups in pharma see med affairsThe differences between access and adoption (and how to impact both)Advances in patient engagement and much moreA quick note-the views expressed here are mine and Pete’s, and don’t reflect those of our employers. At one point I reference the MAPS, Future of Medical Affairs report. You ... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00Hey, what's up everyone? Johnny Casske. Welcome to the Pharmacess Episode 2, the podcast where medical affairs professionals get to learn from each other. And great chat with Pete Piliero, the DP of medical affairs at Olympics. We talk about transitioning from clinical practice to med affairs, the changes in how other groups inform up new medical affairs, the differences between access and adoption, and how to impact both, advances in patient engagement, and much more. A quick note the views expressed here are mine and peak and don't reflect those of our employers.

SPEAKER_00So let's jump in.

SPEAKER_02Good morning, Pete. Morning, John. How are you? I'm doing great. I'm doing great. Let's jump right right into things. So tell me about what you do, uh, your current your current roles, responsibilities, all that good stuff.

SPEAKER_03Sure. Um so uh my name is Pete Pillero. Uh I head up medical affairs at Melinda Therapeutics uh here in New Jersey. I lead a team of medical affairs professionals across the different functions, including uh medical strategy, uh medical information, and field medical. Uh as well outside of my day job, I am involved in the Medical Affairs Professional Society as a member of the board of directors as well as the executive committee.

SPEAKER_02And you've been involved with MAPS for quite some time, correct?

SPEAKER_03Yeah, I was very fortunate to get involved around, I'd say, 2017, um, and uh been part of the growth of what I think is a really, really important organization uh for both the current and future of medical affairs.

SPEAKER_02Yeah, that it's kind of been amazing to see what you all have done with maps. I think I went to the first conference I went to was in Miami, I want to say. And then I went I went to one in New Orleans. And at the time I was going to a lot of different conferences and just the engagement, it was sort of a clearly all the medical affairs people felt like it was by medical affairs people for medical affairs people, and it just had a very different vibe than a lot of other conferences that I that I went to.

SPEAKER_03Yeah, to watch the growth of the organization, both from uh a grassroots effort led uh largely by Kirk Shepherd and a few others, uh, to now being an organization that's approaching 10,000 members and a live, you know, global meeting every year that this year topped our record of over 800 attendees. It's pretty impressive. I think it really says that one, medical affairs is a growing profession, and two, people really wanted to have a place where they can learn, uh their skills, and grow as medical affairs professionals.

SPEAKER_03So we're we're I'm thrilled to be part of the organization, and uh we remain very much focused on our mission of uh growing uh the best medical affairs professionals in the industry.

SPEAKER_02Yeah, and from an outside somewhat outsider's perspective, it's interesting to see changes in medical affairs, even in the maybe six, seven years or so that I've been working directly with them, where it seemed like it went from such a niche uh play to now a lot of times you see HOR access reporting in, patient might be reporting in, and it's just this idea that I think is so necessary of taking scientific information from the beginning, and and it's such a complex thing with patient perspective and access and all these things that are necessary to get the medicines to the patient.

SPEAKER_03Uh absolutely. I mean, I I uh ended up in medical affairs after uh transitioning from uh being in academia as a practicing infectious disease and HIV specialist and clinical researcher, uh and really ended up being a natural transition uh from clinical medicine to what I see as a very clinical-oriented uh part of our industry. Um, so you know, we're we're talking, we're generating science, we're talking about science, uh, we're um uh focused on making sure that clinicians and and others have the right medical information.

SPEAKER_03So these were all things that I think many of us as clinicians did in practice, and now to be able to move over to industry and be part of medical affairs, it was really very natural. So I've been in medical affairs now for over 18 years, and to your earlier point, profession has changed a lot. Um, you know, we we uh were sort of a an ancillary part of the organization when we first started. Um and and medical affairs only started a little bit before that, a little over 20 years ago, and uh and now we are really an integral part of industry.

SPEAKER_02Yeah, it's it seemed like even you know seven, eight, eight years ago, a lot of times medical affairs people were maybe struggling to just not struggling to justify what they were doing, but how do you quantify it? How do you qualify the impact? Um, what changes have you seen in that area as you're communicating with your clinical colleagues or your commercial colleagues? And have you seen their perceptions change?

SPEAKER_03Yeah, absolutely. Um I think let me hone in on the word impact that you used, and I think that's critical to the success of any medical affairs organization in any company. You you do need to demonstrate something that is impactful, and it's not just about numbers. I think we we've gone from uh a numbers game to uh how do we show uh tangible impact uh in a qualitative way?

SPEAKER_03And so I'm not dismissing the need for quantitative metrics, but it's really the qualitative metrics that make a difference for people. How did we in medical affairs uh help achieve access to our medications? Uh how do we help enable appropriate product adoption? Um, those are not the things that medical affairs were built on, you know, 20 years ago. It was really more did you did you disseminate the information?

SPEAKER_03Did you talk to how many KOLs did you talk to? Um, you know, how many medical information responses went out? It was very much a doing organization uh and not a I'll call it a thinking or strategic organization. And now if you establish a the function in your company as a strategic pillar uh of the organization, you will have a seat at the table. And you will uh only get that if you are strategic and impactful.

SPEAKER_03So uh yeah, this and I'd say that that really transition to medical affairs being in a prime role and a prime seat is probably really over the last say seven to eight years. Um what's interesting is the job before this, I was uh head of medical affairs America's at GSK Consumer Health. And interestingly, medical affairs in the consumer side of the business is important as well, but is or I I found it to be behind where we are in innovative pharma side.

SPEAKER_03So, and I think that they're just catching up and uh they will get to the same place we are. It's just uh a different business, and I think there um they were viewed as again more of that doing function and not strategic function. So, one of the things that I enjoyed while I was there was raising that bar and getting people to understand that we are strategic and we can do things that are very impactful.

SPEAKER_02This episode is sponsored by Structured Meetings. It's a Teams app that turns your own Teams incidents into the perfect advisory board platform to save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com. Yeah, I mean, one of the things you mentioned was access. And I mean, I remember this is a couple of years ago, but I was um going to get my COVID shot, right?

SPEAKER_02And I it was at the time where it was really it was hard to get. I was on a waiting list at a Rite Aid or something, and they they called me up and I was I just like ran over there to try to get there before it closed. And where I live in Philadelphia, um it's definitely it's in Germantown, uh, is the name of the neighborhood. It's definitely a like a mixed income area. And as I was there, I was so happy I got my shot, and that you have to wait for the 15 minutes. So I was just watching what was happening, and what I saw was I think six patients come up and try to fill prescriptions and walk away with no medicine because the co-pays were the co-pays were too high, it wasn't covered properly, et cetera, et cetera.

SPEAKER_02And it was just this really kind of striking moment where I was at that point so happy to be getting medicine, right, and and getting this thing solved. And it's it's watching also what lack of access does to people, and who knows, who knows what they had going on. And so this idea of impact, I how do you and this is one of the things that actually MAPS talks about is is kind of medical affairs as the repository for all of these different perspectives because it's really complicated getting drugs to people.

SPEAKER_02So when you're thinking about it from a strategic perspective, how are you sort of managing the interplay with access messaging, science, science messaging, you know, all of the other things that that you need to be involved with in when you're talking to whomever you're talking to?

SPEAKER_03Yeah. So um let's talk about access. And I agree, there's right, there's uh there's access that is uh inhibited by socioeconomic factors, and then there's access that's inhibited by uh payer-related challenges, and for example, formulary status. And you know, the role of medical affairs is not to achieve formulary status, right? There's there's people in market access, which is usually in a commercial organization who are responsible for that.

SPEAKER_03But how does medical affairs impact that access? We impact it again through the science. I mean, that's the beauty of meta affairs. It is a scientific function. And so we in collaboration, another important capability of medical affairs professionals, will work with our market access colleagues and be part of those discussions with what some people call population-based decision makers, you know, people who make decisions for big groups of people. Um, and as part of those conversations, we're not there talking about pricing or anything like that.

SPEAKER_03We're talking about the science. Why is it important that your patients, your customers of, say, insurance company X, have access to this medication? In the same way, we'll talk to HCPs and KOLs about access again, about in the same vein. You know, why is it important that they have access to this antibiotic? Uh, what is the difference it's going to make in terms of their outcome in terms of hospital discharge or even hospital avoidance?

SPEAKER_03Um, and so um uh it's it's bringing that scientific expertise and acumen uh to these discussions that enables access. And then what I like to talk about even more these days is product adoption, because you can have access in a health system, for example, but if clinicians don't understand how and why to use your product, it won't be adopted.

SPEAKER_03And again, our we don't we're not we don't sell anything. We we talk about the science, and that science, uh, if it's solid, if it's if it's good, if it's well communicated, will hopefully help clinicians understand the potential value to the right patient at the right time. And that and that's again, as a clinician, that just resonates really well with me because as clinicians, we have lots of op lots of drugs and treatments that are available, but which is the right one for that individual patient?

SPEAKER_02Can you explain a little more what you mean about the difference between product adoption and and access?

SPEAKER_03Yeah, so access is more can a patient, if their doctor prescribes a medication, can they get it? Can can it can if they're bringing a prescription to the pharmacy, will the pharmacy fill it? Um and if it's not on formulary, they may not fill it, or they may fill it at a much higher price. So that's the access piece, and that's to me a bit more of a commercial part of how patients get drug or treatments.

SPEAKER_03But the adoption is different. The adoption is more about the utilization of the product, so and it's really about HCP adoption, um, healthcare provider adoption. Um, will they select or decide to use your product versus another product? And um when they choose it, are they choosing it with a particular patient in mind? Because not every product is right for every patient.

SPEAKER_03I think we have to again say we stay rooted in that in medical affairs, that you know, we don't want every patient to get our drug necessarily. Um, right? And how do we then help clinicians understand who it's right for? Um, and and I think that's uh uh again a high science nuanced discussion that we try to engage in through MSL scientific exchange, through medical publications, through medical education, and through other types of uh tactics, if you will, that we can lead in medical affairs.

unknownRight.

SPEAKER_02It's not so much about getting the doctors to prescribe your drug, it's getting to prescribe the right drug.

SPEAKER_03Yeah. That's right. Because at the end of the day, you know, again, this is a big part of what we talk about at MAPS, but it's also a big part of what I talk about with my team, which is at the end of the day, what we do is hopefully going to help and improve patient outcomes. That that's really the the mission.

SPEAKER_02Well, speaking of maps, right, the collaboration between uh companies is something that they identify in the the future medical affairs report. It's a great report. I'll I'll link it in the description. Uh, but they also talk about five areas of increasing importance, which uh data dissemination and communication, external relationships, strategic insights, evidence generation, patient engagement. I'm just curious, Pete, which which one are you most excited about and why?

SPEAKER_03Yeah, you know, it's a it's a tough uh choice to make amongst those uh five uh key areas, but I'll I'm gonna so I'm gonna pick two. Um I think strategic insights is a biggie. It's one that we've been talking about for now, I'd say, the last uh five, six years. Um, this importance of uh identifying through the work that we do in medical affairs uh insights, uh new nuggets of information that we can action, that can change our strategy and potentially then change our tactics to ultimately then provide customers, stakeholders, you know, HCPs, patients, payers, etc., with the information they need to make that access or product adoption decision.

SPEAKER_03And we've been we're getting better at it. I think we're identifying or collecting, let me say it this way, we're collecting a lot of data, but not all data are insights. And so we're getting better going through all that data and mining it, but we we need to go beyond that. Um, we we need to uh get better using technology to find those nuggets, uh those those actionable insights, and and then spread them across the pharmaceutical industry infrastructure, meaning uh to uh early development, to clinical development, to commercial.

SPEAKER_03They're not just insights for medical, they're insights from across the infrastructure within the industry. And if we can do that, we can influence potentially portfolio decisions, early development decisions, uh clinical trials, and the right endpoints. Um, and if and if we do that, then hopefully we're delivering in the end better therapeutics, better technologies, uh, and and influencing again the practice of medicine and improving patient outcomes.

SPEAKER_03So that's the first one I'd say. I think the the second one uh is the patient engagement part. You know, this is a really interesting one because for years we've we we talk about the patient a lot and we think about the patient a lot, but medical has never been able to really own the patient. You know, we we we gather information and insights about the patient through our interactions with HCPs, but we're we're we're still fairly removed from actually the patient themselves.

SPEAKER_03Um, sometimes there's patient advocacy organizations that are having those conversations. They those often don't live in medical. Sometimes they do, but they often don't. Um but even there, they're often talking to sort of patient representatives more than patients themselves. So, what I'd like to see medical affairs do over the coming years is figure out to crack that nut and figure out how we can engage more with the patient directly. Not to tell them what to do, but really again gain those insights, those back to the strategic insights part, so that we're developing the therapeutics that they need.

SPEAKER_03We understand the challenges they have with their disease andor their therapies, um, and use that information to uh ultimately uh create better uh tools for them to be successful with their uh treatment of their conditions and diseases. The challenge is that you know there's a there's no really regulatory uh precedence for how to do this. So I think we're gonna have to work uh to to to define that uh so that we in medical affairs can get closer to the patient.

SPEAKER_02Yeah, and it's interesting to me how intermingled it all is. So I've had a client who was who had posted a patient registry uh for the for a rare disease, and they're struggling on how do we how do we get people there? And the question was, do we is it a problem on the patient side? Is it a problem on the provider side? And the answer is kind of both, right? They both need to understand why and the value to that particular audience of participating in order for it to work.

SPEAKER_02So this idea of what's the most important thing, I understand why you said they're all important because they are all important and they all sort of go hand in glove. Um, and even even the strategic insights, right? You can get strategic insights from talking to people, you can get it from observing their online behavior, you can get it from MSL feedback. There's a million ways you can get it, and pharma companies are so big and have so many people working on it that it's almost by nature there's going to be pockets of information even within your own organization that would be helpful to that might not be easy to surface or or things along those lines.

SPEAKER_02But how do you look when you're thinking about strategic insights? Are you are you considering or factoring in, you know, within your own organization where there might be uh areas of expertise that might be untapped, or is it mainly out outside going to the particular audiences?

SPEAKER_03Um that's an interesting question. Um I would say that it's looking at our medical strategy in the context of understanding the overall product strategy, because I think that's important. Where are their opportunities to learn from the external environment what's most important?

SPEAKER_03And and what gaps and needs exist. And by doing that, you can then set certain parameters to listen for information that relates to that strategy. You can then collect it in a way that you can start to digest it either manually, which I see unfortunately a lot of us are still doing, versus using things like NLP and other AI-related tools.

SPEAKER_03And then try to surface those things that you can actually do something about. And that's the hard part, is because there are so many data sources that need to come into play. You mentioned some of them. I'll throw some other ones out there, which is just the scientific literature. There's so much being published every single day. How do you pull in the insights from that? Social media, oh my gosh, there's a lot of medical information, in quotes, I want to say there, that is uh happening on social media, like Twitter, for example.

SPEAKER_03How do you mine that? How do you collect that? It's all unstructured data. And so I think we have to get better, probably as an industry, but certainly in medical affairs, at pulling in all of these data sources uh and uh being able to uh mine them to find the nuggets.

unknownRight.

SPEAKER_02Yeah, you're looking for a needle in a gigantic digital stack. That's exactly right.

SPEAKER_03That's exactly right.

SPEAKER_01Yeah. Um so all right, I know that you have to run to another call.

SPEAKER_02So let me just ask you a kind of concluding question here, which is um what are thinking of the future, the near-term future, next next one to three years, what are you most excited about as it relates to to medical affairs?

SPEAKER_03Yeah, so um I uh love medical affairs, I think, as I probably said earlier on, and uh I think the sky is the limit for medical affairs. So, what I am excited about is to see the further evolution of medical affairs into this strategic powerhouse function that is highly impactful both internally and externally. Um, and uh with that I think will come even greater recognition, which I'd love to see also of the medical affairs function.

SPEAKER_03Um I'm also excited about this potential to get closer to the patient. Um, this kind of elusive goal that we've had that we talk a lot about. And again, I really think we need to crack that nut uh and figure that out. Um and then I think um, you know, just uh continuing to uh help individuals and the function as a whole grow uh and gain more competencies uh that enable them and the function to be more impactful is super exciting to me.

SPEAKER_03I think to me that that's really what MAPS is aiming to do. Uh I try to do it internally in my own company, but MAPS as a big organization now uh is really uh continuing to further uh that mission of raising the bar for medical affairs, and that's extremely exciting to me, and I'm so grateful to be part of it.

SPEAKER_02I love it. The focus on on the patient is um, I mean, that's the exciting point part, right? Is seeing all this science being development or being development being developed, and then you know, ultimately, you know, in rare disease, somebody gets a drug to cure something at times that they thought was a was going to be with them the rest of their life, or millions of other examples. And it's it's really interesting, and I I love sort of the mix of science, some level of business acumen, some level of there's all sorts of things in there.

SPEAKER_02There's marketing, there's taking a message and understanding what's going to resonate, what's important, what needs to be included, what what doesn't. And so it is clearly a strategic role because it's super complex and it's super impactful. Um so with that, we'll we can leave it there. And uh thank you, thank you, Pete.

SPEAKER_03You're welcome, John. Thanks. I appreciate being part of this today.

SPEAKER_02This episode is sponsored by Structured Meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in Teams? And the answer back then was, not really. Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own team's instance.

SPEAKER_02It changes Teams just enough to check all the boxes for what's needed for great ad boards. And also, it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, back to the show.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode